Trial results for a study investigating participant preference for subcutaneous pembrolizumab coformulated with berahyaluronidase alfa (MK-3475A) over intravenous pembrolizumab (MK-3475) were posted on ClinicalTrials.gov on 2026-04-08. The study, involving participants with multiple tumor types, found that 65.3% of participants preferred the subcutaneous formulation.
Background
Pembrolizumab (Keytruda) is an immunotherapy drug. The study focused on its administration in participants with Non-Small Cell Lung Cancer, Renal Cell Carcinoma, and Melanoma.
Trial design
The study (NCT06099782) was a Phase 2 trial with an enrollment of 147 participants. It evaluated participant preference for subcutaneous pembrolizumab coformulated with berahyaluronidase alfa (MK-3475A) compared to intravenous pembrolizumab (MK-3475) administration. The study included participants with Non-Small Cell Lung Cancer, Renal Cell Carcinoma, and Melanoma. The trial's purpose was to assess participant-reported preference, with no hypothesis testing planned.
Key results
The trial's key measurement focused on participant-reported preferences for the subcutaneous (SC) formulation over the intravenous (IV) formulation.
- The "Percentage of Participants Who Prefer Pembrolizumab Plus Berahyaluronidase Alfa Subcutaneous (SC) As Assessed By Patient Preference Questionnaire (PPQ) Question 1" was 65.3% for the Full Analysis Set.
What this means
The results indicate a clear preference among participants for the subcutaneous coformulated pembrolizumab with berahyaluronidase alfa over the intravenous formulation. This preference for subcutaneous administration could offer a more convenient treatment option for patients, potentially improving adherence and quality of life by reducing clinic time associated with intravenous infusions. Such a formulation could be particularly beneficial for patients with Non-Small Cell Lung Cancer, Renal Cell Carcinoma, and Melanoma who require long-term immunotherapy.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT06099782, titled "A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)," were posted on 2026-04-08 on clinicaltrials.gov.